Effects of monascin on anti-inflammation mediated by Nrf2 activation in advanced glycation end product-treated THP-1 monocytes and methylglyoxal-treated wistar rats

Medicine & Life Sciences

• monascin 98%
• Pyruvaldehyde 69%
• Advanced Glycation End Products 58%
• Monocytes 40%
• Wistar Rats 40%
• Receptor for Advanced Glycation End Products 31%
• Inflammation 28%
• Retinoic Acid Receptors 10%
• Heme Oxygenase-1 9%
• Interleukin-1 8%
• Hyperglycemia 7%
• Blood Cells 6%
• Anti-Inflammatory Agents 6%
• Ligands 5%
• Cytokines 5%
• Membranes 4%
• Control Groups 4%
• Serum 3%
• Therapeutics 2%

Agriculture & Biology

• advanced glycation end products 71%
• monocytes 51%
• inflammation 44%
• rats 25%
• receptors 24%
• retinoic acid receptors 18%
• heme oxygenase (biliverdin-producing) 17%
• silymarin 17%
• tumor necrosis factors 16%
• noninsulin-dependent diabetes mellitus 15%
• hyperglycemia 14%
• interleukin-1 14%
• mononuclear leukocytes 14%
• diabetes 13%
• acid treatment 12%
• cytokines 11%
• ligands 11%
• inactivation 10%

Chemical Compounds

• Glycation 63%
• Advanced Glycation End-Product 46%
• Retinoic Acid 42%
• Methylglyoxal 10%
• Antiinflammatory 7%
• Heme 7%
• Antioxidant Agent 6%
• Ligand 3%